EcoDrugPlus

Nuclear Factor Kappa B Subunit 1

Ensembl ID : ENSECRG00000012266
Gene Symbol: NFKB1
3 Cross references
204 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 2

Ensembl ID : ENSECRG00000009444
Gene Symbol: NR1H2
3 Cross references
304 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 3

Ensembl ID : ENSECRG00000021704
Gene Symbol: NR1H3
3 Cross references
392 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 4

Ensembl ID : ENSECRG00000004858
Gene Symbol: NR1H4
3 Cross references
388 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSECRG00000008039
Gene Symbol: NR3C1
3 Cross references
280 Possible Orthologues:

Nucleotide Binding Oligomerization Domain Containing 2

Ensembl ID : ENSECRG00000013650
Gene Symbol: NOD2
3 Cross references
167 Possible Orthologues:

Opioid Receptor Delta 1

Ensembl ID : ENSECRG00000018125
Gene Symbol: OPRD1
3 Cross references
246 Possible Orthologues:

Opioid Receptor Kappa 1

Ensembl ID : ENSECRG00000004611
Gene Symbol: OPRK1
3 Cross references
264 Possible Orthologues:

Opioid Receptor Mu 1

Ensembl ID : ENSECRG00000002528
Gene Symbol: OPRM1
3 Cross references
215 Possible Orthologues:

Opioid Related Nociceptin Receptor 1

Ensembl ID : ENSECRG00000022992
Gene Symbol: OPRL1
3 Cross references
202 Possible Orthologues:

P21 (Rac1) Activated Kinase 4

Ensembl ID : ENSECRG00000000145
Gene Symbol: PAK4
3 Cross references
163 Possible Orthologues:

Parathyroid Hormone 1 Receptor

Ensembl ID : ENSECRG00000009151
Gene Symbol: PTH1R
3 Cross references
199 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).